Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures-Reply

Hannah C Glass^{1

2

3}, Renée A Shellhaas⁴

Affiliations

¹ Department of Neurology, Weill Institute for Neuroscience, University of California, San Francisco, San Francisco.
² Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco.
³ Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco.
⁴ Department of Pediatrics, University of Michigan, Ann Arbor.

Comment

Hannah C Glass et al. JAMA Neurol. 2022.

. 2022 Jan 1;79(1):91-92.

doi: 10.1001/jamaneurol.2021.4112.

Hannah C Glass^{1

2

3}, Renée A Shellhaas⁴

¹ Department of Neurology, Weill Institute for Neuroscience, University of California, San Francisco, San Francisco.
² Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco.
³ Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco.
⁴ Department of Pediatrics, University of Michigan, Ann Arbor.

No abstract available

Comment on

Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures.
Glass HC, Soul JS, Chang T, Wusthoff CJ, Chu CJ, Massey SL, Abend NS, Lemmon M, Thomas C, Numis AL, Guillet R, Sturza J, McNamara NA, Rogers EE, Franck LS, McCulloch CE, Shellhaas RA. Glass HC, et al. JAMA Neurol. 2021 Jul 1;78(7):817-825. doi: 10.1001/jamaneurol.2021.1437. JAMA Neurol. 2021. PMID: 34028496 Free PMC article.
Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures.
Crawford J, Gold J, Haas R. Crawford J, et al. JAMA Neurol. 2022 Jan 1;79(1):90-91. doi: 10.1001/jamaneurol.2021.4109. JAMA Neurol. 2022. PMID: 34779830 No abstract available.